Rare Bone Disease
Osteogenesis imperfecta is the central therapeutic focus, with research activity directed toward reducing fracture risk and improving skeletal outcomes in people affected by this inherited connective tissue disorder.
- Fracture prevention
- Skeletal fragility
- Inherited bone disease
The sponsor’s research interest is concentrated on clinical approaches relevant to bone strength and the management of recurrent fractures in a rare paediatric and adult orthopaedic condition.
Bone Metabolism
Trial activity includes therapies associated with bone remodelling and mineral metabolism, reflecting interest in treatments that influence bone formation and resorption in osteogenesis imperfecta.
- Parathyroid hormone therapy
- Bisphosphonate treatment
- Anti-resorptive therapy
Research in this area is closely tied to preserving bone integrity and addressing the underlying imbalance that contributes to fragility and low bone mass.
Fracture Outcomes
The sponsor’s clinical interest extends to outcomes linked with confirmed bone fracture, using imaging-based assessment to understand whether treatment strategies can lower the burden of skeletal injury.
- X-ray confirmed fracture
- Imaging assessment
- Clinical fracture burden
This focus aligns with the need to evaluate how treatment choices affect day-to-day risk in patients living with fragile bones and repeated orthopaedic complications.
Hospital-Based Specialist Care
As a hospital and healthcare facility sponsor in Edinburgh, NHS Lothian is involved in specialist research supported through collaborating sites across multiple countries, with activity centred on coordinated care for a rare musculoskeletal disorder.
- Specialist clinical services
- Multi-site collaboration
- Rare disease care
The clinical setting is relevant to patients requiring ongoing assessment, long-term management, and treatment planning for complex bone fragility.
